Skadden is advising Valeant Pharmaceuticals International, Inc. and Valeant Europe B.V. on the acquisition of Mercury (Cayman) Holdings, the holding company of Egypt's Amoun Pharmaceutical Company S.A.E., announced July 17, for approximately $800 million plus contingent payments.

BACK TO TOP